Aspen Park Pharmaceuticals Overview

  • Founded
  • 2014

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees
  • Latest Deal Type
  • M&A

Aspen Park Pharmaceuticals General Information

Description

Developer of novel therapies for premature ejaculation in men. The company focuses on the development and commercialization of novel therapies for men's health diseases and conditions, including male secondary hypogonadism, prostate cancer, and sexual dysfunction.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 944 Park Avenue
  • New York, NY 10028
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aspen Park Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 31-Oct-2016 00.000 Completed Generating Revenue
2. Seed Round 31-Mar-2016 00.000 00.000 Completed Startup
1. Early Stage VC (Series A) 10-Dec-2014 Completed Startup
To view Aspen Park Pharmaceuticals’s complete valuation and funding history, request access »

Aspen Park Pharmaceuticals Patents

Aspen Park Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190133977-A1 Delayed release oral tamsulosin hydrochloride Inactive 04-May-2016 000000000
CA-3023106-A1 Delayed release oral tamsulosin hydrochloride Pending 04-May-2016 000000000
EP-3452016-A1 Delayed release oral tamsulosin hydrochloride Inactive 04-May-2016 000000000
AU-2017260505-A1 Delayed release oral tamsulosin hydrochloride Inactive 04-May-2016 0000000000
AU-2017222567-A1 Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism Inactive 25-Feb-2016 A61K31/138
To view Aspen Park Pharmaceuticals’s complete patent history, request access »

Aspen Park Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Harry Fisch MD Co-Founder, Chairman & Chief Scientific Officer
Mitchell Steiner Ph.D Co-Founder, President, Managing Director & Chief Executive Officer
To view Aspen Park Pharmaceuticals’s complete executive team members history, request access »

Aspen Park Pharmaceuticals Board Members (2)

Name Representing Role Since
Elgar Peerschke Self Board Member 000 0000
Sanjeev Dheer Self Board Member 000 0000
To view Aspen Park Pharmaceuticals’s complete board members history, request access »

Aspen Park Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial